NMP and NEP
These substances were identified for action under the Chemicals Management Plan (CMP).
| CAS RN | Common name (abbreviation) |
DSL name | Public comments on the first draft screening assessment | Updated draft assessment | Risk management scope | Proposed conclusion on section 64 criteria | Follow-up activities |
|---|---|---|---|---|---|---|---|
| 872-50-4 | N-Methylpyrrolidone (NMP) | 2-Pyrrolidinone, 1-methyl | HTML | HTML | HTML | Meets one or more of the criteria | Refer to risk management scope |
| 2687-91-4 | N-Ethylpyrrolidone (NEP) | 2-Pyrrolidinone, 1-ethyl | None | Does not meet | Under consideration |
| Date | Activity |
|---|---|
| January 2025 | Anticipated publication of the final assessment and proposed risk management approach. |
| January 27, 2024 | Publication and start of a 60-day public comment period on the Updated Draft Screening Assessment for NMP and NEP (including follow-up activities for NEP) and the Risk Management Scope for 2-pyrrolidinone, 1-methyl- (NMP). The related notice was published in the Canada Gazette, Part I: Vol. 158, No. 4. |
| February 4, 2017 | Publication and start of 60-day public comment period on the first draft screening assessment (including follow-up activities). The related notice was published in the Canada Gazette, Part I: Vol. 151, No. 5. |
Background
A draft screening assessment for NMP and NEP was published in February 2017. Since then, new information became available regarding exposure to products available to consumers containing NMP and NEP that had the potential to alter assessment conclusions. As a result, the draft screening assessment was updated.
Page details
- Date modified: